Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 15, 2004. The report primarily addresses corporate governance updates, specifically the appointment of new Non-Executive Directors and changes in directors' share interests, rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding board composition and share transactions, not a financial results report.
Material Changes
- Board Appointments: Sir Christopher Gent was appointed as Non-Executive Deputy Chairman and Sir Deryck Maughan as Non-Executive Director, effective June 1, 2004.
- Share Transactions: On June 14, 2004, the GlaxoSmithKline Employee Trust transferred 4,570 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details compliance with the Financial Services Authority's Listing Rules regarding director appointments and interests.
Investor Verification Points
- Confirm the effective date of Sir Christopher Gent and Sir Deryck Maughan's board appointments (June 1, 2004).
- Verify the transfer of 4,570 Ordinary Shares from the GSK Trust to employee plan participants.
- Note that neither new director holds notifiable interests in GSK Ordinary Shares or American Depositary Shares.
- Review the directors' past and current roles at other publicly quoted companies (e.g., Lehman Brothers, Citibank, Vodafone, NYSE).